Abstract
BackgroundThis paper describes a blind randomized controlled trial (RCT) designed to evaluate the effect of gonadotropin-releasing hormone agonist (GnRH-a) administration on outcomes of intracytoplasmic sperm injection (ICSI) in subjects stimulated with the gonadotropin-releasing hormone (GnRH) antagonist protocol. A total of 268 women who underwent ICSI cycles with GnRH antagonist ovarian stimulation protocol were included in the study. Patients were randomly assigned to the intervention (GnRH-a) and control groups. The intervention group received a single dose injection of triptorelin (0.1 mg) subcutaneously 6 days after oocyte retrieval while the control group received placebo. The rates of chemical and clinical pregnancy were defined as the primary outcome values.ResultsTwo hundred forty participants accomplished the study, and their data were analyzed. No significant difference was detected between the chemical pregnancy rates of the intervention and control groups. However, the clinical pregnancy rate was significantly higher in the GnRH-a group than in the placebo group.ConclusionsThe findings of the present study suggest that the GnRH-a support in the luteal phase can result in a significant improvement of pregnancy rates in ICSI cycles following the ovarian stimulation with GnRH antagonist protocol.
Highlights
This paper describes a blind randomized controlled trial (RCT) designed to evaluate the effect of gonadotropin-releasing hormone agonist (GnRH-a) administration on outcomes of intracytoplasmic sperm injection (ICSI) in subjects stimulated with the gonadotropin-releasing hormone (GnRH) antagonist protocol
Low response according to Bologna criteria, repeated implantation failure (RIF), polycystic ovary syndrome (PCOS), endometriosis, uterine abnormalities, hormonal disorders, ovarian hyperstimulation syndrome (OHSS), failed fertilization, less than two embryos available for transfer, Treatment protocol Patients were pretreated with 2 mg of oral estradiol valerate (Aburaihan Co., Tehran, Iran) twice daily from day 21 of the natural cycle continued until days 2–4 of the new cycle
Our results showed no significant difference in the chemical pregnancy rates between the two groups
Summary
This paper describes a blind randomized controlled trial (RCT) designed to evaluate the effect of gonadotropin-releasing hormone agonist (GnRH-a) administration on outcomes of intracytoplasmic sperm injection (ICSI) in subjects stimulated with the gonadotropin-releasing hormone (GnRH) antagonist protocol. The continuously high levels of estradiol inhibit the luteinizing hormone (LH) secretion by hypophysis. This effect shortens the luteal phase and Administration of gonadotropin-releasing hormone agonist (GnRH-a) has been introduced recently as a beneficial luteal phase support [7, 8]. Recent studies have shown the positive effect of a single-dose GnRH-a administration on the luteal phase in ICSI cycles [9,10,11,12,13].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
